Atrial natriuretic peptide protects against acute ischemic renal failure in the rat.

AUTOR(ES)

Shaw, S G

RESUMO

Because of its ability to increase glomerular filtration, antagonize the actions of vasoconstrictors, and produce vasodilation, alpha human atrial natriuretic peptide (alpha-hANP) was evaluated for its potentially beneficial effects in experimental ischemic renal failure induced by 45-60 min of renal artery occlusion in bilaterally or unilaterally renally intact Sprague-Dawley rats. After ischemia, a 4-h intrarenal infusion of alpha-hANP restored 14C-inulin clearances in bilaterally and unilaterally intact animals from 0.05 +/- 0.006 and 0.05 +/- 0.01 ml/min per 100 g to 0.314 +/- 0.04 and 0.25 +/- 0.01 ml/min per 100 g, respectively (P less than 0.001, n = 8), compared with normal values of 0.49 +/- 0.023 ml/min per 100 g. Histologically, there was a progressive decrease in medullary hyperemia and prevention of intratubular cell shedding and granulocyte margination as a result of the 4-h alpha-hANP infusion such that after 24 and 48 h the histological appearance of the tissue was essentially normal. The results show that a 4-h intrarenal infusion of alpha-hANP after renal ischemia can preserve glomerular filtration rate and reduce renal tissue damage.

Documentos Relacionados

• Oxygen free radicals in ischemic acute renal failure in the rat.
• Ischemic acute renal failure and antioxidant therapy in the rat. The relation between glomerular and tubular dysfunction.
• Oxytocin mediates atrial natriuretic peptide release and natriuresis after volume expansion in the rat.
• Acute renal failure with selective medullary injury in the rat.
• Physiologic regulation of atrial natriuretic peptide receptors in rat renal glomeruli.